Delivery Order SPE2DB20D2104-SPE2DB25FNAAR
- Not listed
- The Defense Logistics Agency awarded a $15,567.60 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of UBRELVY 100 mg tablets (unit dose, 10s). This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a prescription migraine treatment, indicating this delivery order supports military or federal...
- The Defense Logistics Agency awarded a $5,423.70 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-unit dose packages) with a completion deadline of September 2, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $34,376.11 for UBRELVY 100 mg tablets (16-count unit dose packages) on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $29,146.75 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16-count unit dose packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting AmerisourceBergen's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order valued at $5,427.25 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packs (16 count). This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 25, 2025. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist indicated for acute migraine treatment. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,413.91 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10s. This is a non-set-aside competitive award with a completion date of August 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is an acute treatment medication for migraine headaches, representing routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $4,338.57 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging, quantities of 16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and was competitively awarded without set-aside designation. The pharmaceutical will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 units, with a ceiling value of $18,754.48. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 10, 2025. The award is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNAARDelivery Order
The Defense Logistics Agency awarded a $16,964.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (10-count). The contract, which is a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, has an ultimate completion date of September 11, 2025. UBRELVY is an FDA-approved acute migraine treatment medication, and this delivery supports the pharmaceutical supply needs of military and federal healthcare systems. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's comprehensive Pharmaceutical Prime Vendor Global Program IDC valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through the DLA Medical Supply Chain, supplying an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare operations worldwide. The no-set-aside designation reflects the competitive nature of the underlying IDC award, which positions AmerisourceBergen to efficiently fulfill federal medical supply requirements through this flexible contract vehicle serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.0k | 9/10/25 |